Navigation Links
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Date:12/9/2008

anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." During clinical studies, two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their prescribing physicians are enrolled in the Soliris Safety Registry which is part of a special risk management program that involves initial and continuing education and long-term monitoring for detection of new safety findings.

Please see full prescribing information at www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for Alexion's first product, Soliris, for all patients with PNH, and Alexion began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the EC granted marketing approval for Soliris in the European Union for all patients with PNH. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for add
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
2. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
3. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
10. NIST studies how new helium ion microscope measures up
11. SpectraCell Laboratories Now Measures Vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 01, 2015 Park Systems, ... selected to receive the prestigious “Best Analytic Instrumentation ... NX10 is the premium research-grade True Non-Contact AFM, ... linearity, closed-loop detector noise, and minimized thermal drift. ... n, which allows images with a single click, ...
(Date:4/1/2015)... April 1, 2015  VLP Therapeutics, LLC. ("VLP"), a ... the research and development of therapeutic and preventative vaccines ... and proprietary vaccine technology, today announced that it has entered ... Medicine at Nagasaki University in ... VLP,s research and development of dengue vaccine candidates. ...
(Date:4/1/2015)... 1, 2015  ValGenesis Inc., the market leader in ... it has completed its Service Organization Controls 2 (SOC ... Professional Standards) for the period of January 1 st ... Logo - ... The SOC 2 examination is performed ...
(Date:4/1/2015)... 1, 2015 Goldman Small Cap Research, a ... and microcap sectors, announced today that it has issued ... PMCB), a publicly traded clinical stage biotechnology company focused ... To view the sponsored research article, along with disclosures ... please visit www.GoldmanResearch.com .  In ...
Breaking Biology Technology:Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4
... Expanded Commercialization of the Revolutionary ... Accuri C6 Flow Cytometer(R) System--, ... Inc., a life,sciences company developing revolutionary bench-top flow cytometer ... C financing led by,Fidelity Biosciences and Flagship Ventures. Current ...
... Mich., July 8 GeneGo, Inc., the leading,systems ... Center,at Yale has become a certified GeneGo Center ... GeneGo,s MetaCore, training and advanced,support., The W. ... of the largest biotechnology laboratories of its kind ...
... TechCFO, a leading provider of outsourced CFO-level financial and management services ... Strickland as Partner to its Boston office. Strickland is the latest ... of last year. , ... Cambridge, MA (PRWEB) July ...
Cached Biology Technology:Accuri Cytometers Completes $13 Million Series C Financing 2Accuri Cytometers Completes $13 Million Series C Financing 3Accuri Cytometers Completes $13 Million Series C Financing 4Yale Keck Microarray Center Becomes a GeneGo Center of Excellence 2TechCFO Adds Gary Strickland as Partner in Boston Office 2
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... for some time that exercise induces neurogenesis in a ... the underlying mechanism was not fully understood. The hippocampus ... and is one of the brain regions where new ... precursor cell maturation , The researchers demonstrated that ...
... described as "orphan diseases, too small to be noticed, ... Lorenzo,s Oil, rare diseases are getting unprecedented attention today ... and marketing new medicines that promise fuller lives for ... That,s the finding of a major examination, published today ...
... at protecting leaves from being chomped by slugs, suggests research ... Although they lurk in the soil, they seem to protect ... amount of damage slugs do to individual plants. Spanish ... worst alien species in Europe and are considered a pest ...
Cached Biology News:Serotonin mediates exercise-induced generation of new neurons 2Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 2Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 3Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 4Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 5
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
... PS10 ProteinChip Arrays are preactivated with carbonyl ... primary amine groups. The PS10 array contains ... PS1 array, but with an updated hydrophobic ... chips with 2 mm diameter spots spatially ...
...
Biology Products: